| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/24/2012 | US8101188 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 01/24/2012 | US8101181 Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| 01/24/2012 | US8101176 Compositions and methods related to TIM-3, a TH1-specific cell surface molecule |
| 01/24/2012 | US8101165 Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors |
| 01/24/2012 | CA2684447C Sulfonyl amide derivatives for the treatment of abnormal cell growth |
| 01/24/2012 | CA2677313C Pyrimidinylaminobenzamide derivatives and their use as inhibitors of tyrosine kinases |
| 01/24/2012 | CA2670760C Naphthyridine compounds as inhibitors of akt activity |
| 01/24/2012 | CA2579810C Stable pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide |
| 01/24/2012 | CA2571409C Neoglycorandomization and digitoxin analogs |
| 01/24/2012 | CA2526578C Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| 01/24/2012 | CA2518169C A recombinant constructed by a virus vector and a human tumor suppressor gene and its use |
| 01/24/2012 | CA2498559C Indole derivatives or benzimidazole derivatives for modulating i.kappa.b kinase |
| 01/24/2012 | CA2496698C 5-h-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| 01/24/2012 | CA2493644C Composition for promoting the proliferation of lactobacillus casei subsp. casei |
| 01/24/2012 | CA2455227C Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 01/24/2012 | CA2431196C Black tea extract for prevention of disease |
| 01/24/2012 | CA2410828C Duplexed parvovirus vectors |
| 01/24/2012 | CA2406168C Polyamide nucleic acid derivatives, agents and methods for producing same |
| 01/24/2012 | CA2402092C 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| 01/24/2012 | CA2386920C Oncolytic virus |
| 01/24/2012 | CA2370763C Peptide epitopes recognized by disease promoting cd4+ t lymphocytes |
| 01/24/2012 | CA2269204C Anti-erbb2 antibodies |
| 01/24/2012 | CA2221318C High affinity oligonucleotide ligands to growth factors |
| 01/20/2012 | CA2735631A1 Curcumin formulations and methods for making such formulations |
| 01/19/2012 | WO2012009707A2 Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
| 01/19/2012 | WO2012009703A2 Targeted nanoparticles for cancer and other disorders |
| 01/19/2012 | WO2012009663A2 New compounds for treating cancer and other diseases |
| 01/19/2012 | WO2012009611A2 Methods and compositions for cancer immunotherapy |
| 01/19/2012 | WO2012009519A1 Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives |
| 01/19/2012 | WO2012009510A1 Azaindazole compounds |
| 01/19/2012 | WO2012009508A2 Microrna compositions and methods related thereto |
| 01/19/2012 | WO2012009499A2 Assessing thyroid neoplasms and treating cancer |
| 01/19/2012 | WO2012009475A1 Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| 01/19/2012 | WO2012009471A1 Anti-angiogenic agent and method of using such agent |
| 01/19/2012 | WO2012009289A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases |
| 01/19/2012 | WO2012009288A2 Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| 01/19/2012 | WO2012009262A2 Diclofenac salt of tramadol |
| 01/19/2012 | WO2012009080A2 Device for radiation-activated localized delivery of treatment agents |
| 01/19/2012 | WO2012008908A1 Cell therapy |
| 01/19/2012 | WO2012008765A2 Pharmaceutical composition for treating or preventing cancer |
| 01/19/2012 | WO2012008762A2 Composition comprising extracts or fractions of specific plants, use thereof and process for preparing the extracts |
| 01/19/2012 | WO2012008711A2 Erlotinib dichloroacetate and anti-cancer agent comprising the same |
| 01/19/2012 | WO2012008594A1 Method for detecting malignant tumor cells |
| 01/19/2012 | WO2012008564A1 Nitrogenated aromatic heterocyclic ring derivative |
| 01/19/2012 | WO2012008563A1 Nitrogenated aromatic heterocyclic ring derivative |
| 01/19/2012 | WO2012008549A1 Heterocyclic ring compound |
| 01/19/2012 | WO2012008508A1 Heterocyclic ring compound |
| 01/19/2012 | WO2012008507A1 Therapeutic agent for cancer |
| 01/19/2012 | WO2012008397A1 Anti-epha2 antibody and use thereof |
| 01/19/2012 | WO2012008302A1 Method for preparing novel hipsc by means of mirna introduction |
| 01/19/2012 | WO2012008301A1 Method for producing novel hipsc by means of sirna introduction |
| 01/19/2012 | WO2012007948A2 CYTOTOXIC Ti (IV) COMPOUNDS |
| 01/19/2012 | WO2012007926A1 Substituted imidazoquinoline derivatives as kinase inhibitors |
| 01/19/2012 | WO2012007896A1 Multifunctional antibody conjugates |
| 01/19/2012 | WO2012007576A1 Superior efficacy of cd37 antibodies in cll blood samples |
| 01/19/2012 | WO2012007562A1 Cyclotetrapeptides with pro-angiogenic properties |
| 01/19/2012 | WO2012007493A1 Purine compounds selective for ρi3κ p110 delta, and methods of use |
| 01/19/2012 | WO2012007416A1 Bicyclic pyrimidines |
| 01/19/2012 | WO2012007409A1 N-substituted pyrrolidines |
| 01/19/2012 | WO2012007137A1 Peptide for use in the treatment of breast cancer and/or bone metastases |
| 01/19/2012 | WO2012007008A1 Inhibitors of hdme |
| 01/19/2012 | WO2012007007A1 Inhibitors of hdme |
| 01/19/2012 | WO2012006960A1 NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| 01/19/2012 | WO2012006958A1 Amids substituted indazole derivativees as ploy(adp-ribose)polymerase inhibitors |
| 01/19/2012 | WO2012006938A1 Pharmaceutical composition capable of targeted release of trace element, and preparation method and application of pharmaceutical composition |
| 01/19/2012 | WO2012006864A1 Triterpenoid saponin compounds, preparation methods and uses thereof |
| 01/19/2012 | WO2012006780A1 Phthalocyanine-serum albumin complex, method for preparation and use thereof |
| 01/19/2012 | WO2012006718A1 Carbohydrate hapten-based anti-cancer vaccines and antibody drugs |
| 01/19/2012 | WO2011147762A3 Stabilized radiopharmaceutical composition |
| 01/19/2012 | WO2011137319A3 Stabilized fibronectin domain compositions, methods and uses |
| 01/19/2012 | WO2011136469A3 Pharmaceutical composition using connective tissue growth factor |
| 01/19/2012 | WO2011129936A3 Compositions and methods for the prevention and treatment of cancer |
| 01/19/2012 | WO2011113005A3 Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo) |
| 01/19/2012 | WO2011112915A3 Methods and compositions containing fc fusiong proteins for enhancing immune responses |
| 01/19/2012 | WO2011112057A3 Novel conditionally replication-competent adenovirus and a method for producing the same |
| 01/19/2012 | WO2011106650A3 Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease |
| 01/19/2012 | WO2011106376A3 Use of microvesicles in the treatment of medical conditions |
| 01/19/2012 | WO2011103289A3 Imidazole-2, 4-dione inhibitors of casein kinase 1 |
| 01/19/2012 | WO2011102660A3 A novel 5-membered heterocycle derivatives and manufacturing process thereof |
| 01/19/2012 | WO2011102626A3 Polyazamacrocyclic compound, and a production method and a biomedical use therefor |
| 01/19/2012 | WO2011098762A3 Antibodies against cxcr4 |
| 01/19/2012 | WO2010131733A9 Anti-axl antibody |
| 01/19/2012 | US20120016467 Polymer-based, sustained release drug delivery system |
| 01/19/2012 | US20120016340 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 01/19/2012 | US20120016338 Chemoablation of tissue using biodegradable, solid salt dosage forms |
| 01/19/2012 | US20120016038 Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
| 01/19/2012 | US20120016034 Polymorphic Form Of N-(S)-(3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-6-Methoxyphenyl)-1-(2,3-Dihydroxypropyl)Cyclopropane-1-Sulfonamide And Uses Thereof |
| 01/19/2012 | US20120016033 Small Molecule Antagonists of Phosphatidylinositol-3,4,5-Triphosphate (PIP3) and Uses Thereof |
| 01/19/2012 | US20120016031 Biphenyl compound selective agonists of gamma rar receptors |
| 01/19/2012 | US20120016019 Pharmaceutical composition for treating or preventing cancer |
| 01/19/2012 | US20120016017 Pharmaceutical composition for treating or preventing cancer |
| 01/19/2012 | US20120016013 Anti-cancer oligodeoxynucleotides |
| 01/19/2012 | US20120016012 RNAi MOLECULE TARGETING THYMIDYLATE SYNTHASE AND APPLICATION THEREOF |
| 01/19/2012 | US20120016007 Small interference rna complex with increased intracellular transmission capacity |
| 01/19/2012 | US20120016003 Pot1 alternative splicing variants |
| 01/19/2012 | US20120016002 Patient Selection and Therapeutic Methods Using Markers of Prostaglandin Metabolism |
| 01/19/2012 | US20120015998 Phototherapy methods and devices comprising emissive aryl-heteroaryl compounds |
| 01/19/2012 | US20120015995 Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| 01/19/2012 | US20120015993 Novel Pharmaceutical Forms, and Methods of Making and Using the Same |
| 01/19/2012 | US20120015992 Napthalene-Based Inhibitors of Anti-Apoptotic Proteins |